Brain Tumor, Pediatric, Brainstem Glioma, Brain Tumor, Pediatric, Recurrent
Conditions
Brief summary
This Protocol is a pilot, clinical interventional study to selected patients between five and fourteen years of both sexes, carriers of the diagnosis of glioma brain stem and high grade recurrent in the central nervous system tumors, in whom there has been no response to conventional-based surgery/radiation/chemotherapy treatment or whose location does not allow treatment with conventional measures, and that already have an indication for a neurosurgical palliative procedure. It will be a close pharmacovigilance on possible adverse effects related to the nanomaterial based on the profile of cisplatin (chemotherapeutic platinum derivative), since documented toxicity data are not counted for NPt-Ca. Quality of life will be documented with PedsQL Cancer Module© and tumor size by magnetic resonance brain images.
Interventions
DRUGPlatinum acetylacetonate (1% wt) supported by sol-gel technology functionalized titania
Sol-gel process Pt(acac)2- F-TiO2 nanostructured material with antitumoral activity used as an alternative in the treatment of cancer tumors. The biocatalysts were prepared by the sol-gel route using the complex Pt(acac)2.
Sponsors
Hospital Infantil de Mexico Federico Gomez
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
5 Years to 14 Years
Healthy volunteers
No
Inclusion criteria
* Histopathological diagnosis or MRI of the brain stem or tumor of recurrent high-grade glioma. * Indication of palliative surgical treatment by neurosurgery. * Good general condition, enabling the realization of surgical treatment. * Scale Lansky \> 20) * conventional treatment (surgery, radiotherapy, and chemotherapy) failed or not applicable to the patient.
Exclusion criteria
* Patients with emerging infectious diseases or fever in the last 72 hours prior to placement of the NPt-Ca. * Patients whose parents/carers do not authorize expressly the realization of procedure with knowledge of its experimental nature, are not agreed or established their commitment to meet follow-up parameters established by this Protocol. * Patients with surgical complications prior to placement of the NPt-Ca. * Patients in which the size and location of the lesion do not allow their surgical approach or an increase in volume by infiltration of the lesion with 3 ml of volume of NPt-Ca. * Patient whose neurological condition do not allow the implementation of MRI without anesthesia.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in the quality of life using the PedsQL Cancer Module© | Preoperative and at 1.3, 6, 12, 18 and 24 months. | Measures of the change of quality of life pre and after the administration of NPt-Ca using the questionnaire PedsQL Cancer Module© |
| Change in tumor size | Immediate, 1, 2, 3, 6, 8, 10, 12, 18 and 24 months. | Change in tumor size after the administration of NPt-Ca using volumetric measures on the brain magnetic resonance. |
Countries
Mexico
Outcome results
None listed